AhmadMahdiTuffahaMD
Nephrology • Kansas City, KSAssistant Professor, Internal Medicine, University Kansas School of Medicine
Dr. Tuffaha is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3901 Rainbow Blvd
# Stop
Kansas City, KS 66160Phone+1 913-588-6074Fax+1 913-588-3867
Education & Training
University of Missouri-Kansas City School of MedicineResidency, Internal Medicine, 2007 - 2010
University of Jordan Faculty of MedicineClass of 2005
Certifications & Licensure
KS State Medical License 2012 - 2025
MO State Medical License 2021 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Open-Label Phase 3 Long-Term Safety Study of Migalastat Start of enrollment: 2011 Oct 14
- Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients Start of enrollment: 2012 Oct 01
- Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease Start of enrollment: 2015 Mar 14
Publications & Presentations
PubMed
- 318 citationsTreatment of Fabry’s Disease with the Pharmacologic Chaperone MigalastatDominique P. Germain, Derralynn Hughes, Kathleen Nicholls, Daniel G. Bichet, Roberto Giugliani
The New England Journal of Medicine. 2016-08-10 - 23 citationsClinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy.Peter W. Santos, Jianghua He, Ahmad Tuffaha, James B. Wetmore
International Urology and Nephrology. 2017-10-20 - 75 citationsPegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year...Raphael Schiffmann, Ozlem Goker-Alpan, Myrl Holida, Pilar Giraldo, Laura Barisoni
Journal of Inherited Metabolic Disease. 2019-04-08
Journal Articles
- Dermatomyositis followed by pemphigus foliaceusz a case report and possible mechanismAhmad M. Tuffaha, Nabih I. Abdou, Rheumatology Reports, 10/27/2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
